Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPREX Anemia Management in Predialysis CRF
NCT00338000Phase 4Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2001
- Modality
- Biologic, rProtein (Recombinant Protein)
01
Overview
Phase 4, open-label, single-arm trial of epoetin alfa in anemia, sponsored by Janssen Pharmaceutical. Primary endpoint: Hemoglobin change - reach of target Hb levels at 9 months. Started Jun 2001; status: completed.
02
Drugs
epoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00338000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00338000.